Online inquiry

IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5527MR)

This product GTTS-WQ5527MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL17A&IL17F gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002190.3; NM_052872.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605; 112744
UniProt ID Q16552; Q96PD4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ5527MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11779MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MK-3222
GTTS-WQ6535MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CX-191
GTTS-WQ10220MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LFB-R593
GTTS-WQ4996MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA C4G1
GTTS-WQ10193MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LDP-02
GTTS-WQ12161MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MORAb-009
GTTS-WQ6986MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ETI-204
GTTS-WQ10415MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY2439821
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW